View : 1926 Download: 836

Full metadata record

DC Field Value Language
dc.contributor.author문영철*
dc.date.accessioned2016-08-27T04:08:42Z-
dc.date.available2016-08-27T04:08:42Z-
dc.date.issued2015*
dc.identifier.issn1949-2553*
dc.identifier.otherOAK-16231*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/217938-
dc.description.abstractThis prospective observational study evaluated the efficacy and safety of long-term decitabine treatment in patients with myelodysplastic syndrome (MDS). Decitabine 20 mg/m(2)/day was administered intravenously for 5 consecutive days every 4 weeks to MDS patients in intermediate-1 or higher International Prognostic Scoring System (IPSS) risk categories. Active antimicrobial prophylaxis was given to prevent infectious complications. Overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and time to response were evaluated, as were adverse events. The final analysis included 132 patients. IPSS risk was intermediate-2/high in 34.9% patients. The patients received a median of 5 cycles, with responders receiving a median of 8 cycles (range, 2-30). ORR was 62.9% (complete response [CR], 36; partial response [PR], 3; marrow complete response [mCR], 19; and hematologic improvement, 25). Among responders, 39% showed first response at cycle 3 or later. OS at 2 years was 60.9%, with 17% progressing to acute myeloid leukemia. PFS at 2 years was 51.0%. Patients achieving mCR showed comparable survival outcomes to those with CR/PR. With active antibiotic prophylaxis, febrile neutropenia events occurred in 61 of 1,033 (6%) cycles. Long-term decitabine treatment with antibiotic prophylaxis showed favorable outcomes in MDS patients, and mCR predicted favorable survival outcomes.*
dc.languageEnglish*
dc.publisherIMPACT JOURNALS LLC*
dc.subjectdecitabine*
dc.subjectlong-term treatment*
dc.subjectmyelodysplastic syndrome*
dc.titleA prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome*
dc.typeArticle*
dc.relation.issue42*
dc.relation.volume6*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.startpage44985*
dc.relation.lastpage44994*
dc.relation.journaltitleONCOTARGET*
dc.identifier.wosidWOS:000369908800068*
dc.identifier.scopusid2-s2.0-84953373584*
dc.author.googleJeong, Seong Hyun*
dc.author.googleKim, Yoo-Jin*
dc.author.googleLee, Je-Hwan*
dc.author.googleKim, Yeo-Kyeoung*
dc.author.googleKim, Soo Jeong*
dc.author.googlePark, Sung Kyu*
dc.author.googleDo, Young Rok*
dc.author.googleKim, Inho*
dc.author.googleMun, Yeung-Chul*
dc.author.googleKim, Hoon Gu*
dc.author.googleLee, Won Sik*
dc.author.googleYi, Hyeon Gyu*
dc.author.googleJoo, Young-Don*
dc.author.googleChoi, Chul Won*
dc.author.googleKim, Suk Ran*
dc.author.googleNa, Sang Min*
dc.author.googleJang, Jun Ho*
dc.contributor.scopusid문영철(7003363716)*
dc.date.modifydate20240123100838*
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
001.pdf(1.32 MB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE